GlaxoSmithKline PLC (GSK) - Total Assets
Based on the latest financial reports, GlaxoSmithKline PLC (GSK) holds total assets worth GBX61.34 Billion GBX (≈ $7.46 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GSK net asset value for net asset value and shareholders' equity analysis.
GlaxoSmithKline PLC - Total Assets Trend (1986–2024)
This chart illustrates how GlaxoSmithKline PLC's total assets have evolved over time, based on quarterly financial data.
GlaxoSmithKline PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
GlaxoSmithKline PLC's total assets of GBX61.34 Billion consist of 28.6% current assets and 71.4% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 6.5% |
| Accounts Receivable | GBX6.93 Billion | 11.7% |
| Inventory | GBX5.67 Billion | 9.5% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX15.52 Billion | 26.1% |
| Goodwill | GBX6.98 Billion | 11.7% |
Asset Composition Trend (1986–2024)
This chart illustrates how GlaxoSmithKline PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GSK market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GlaxoSmithKline PLC's current assets represent 28.6% of total assets in 2024, a decrease from 67.7% in 1986.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2024, up from 1.9% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 1986.
- Asset Diversification: The largest asset category is intangible assets at 26.1% of total assets.
GlaxoSmithKline PLC Competitors by Total Assets
Key competitors of GlaxoSmithKline PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥1.60 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
GlaxoSmithKline PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.84 | 0.81 | 0.91 |
| Quick Ratio | 0.55 | 0.53 | 0.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-3.49 Billion | GBX-4.16 Billion | GBX-1.90 Billion |
GlaxoSmithKline PLC - Advanced Valuation Insights
This section examines the relationship between GlaxoSmithKline PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.45 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | GBX59.46 Billion |
| Market Capitalization | $929.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values GlaxoSmithKline PLC's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: GlaxoSmithKline PLC's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GlaxoSmithKline PLC (1986–2024)
The table below shows the annual total assets of GlaxoSmithKline PLC from 1986 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX59.46 Billion ≈ $7.23 Million |
+0.78% |
| 2023-12-31 | GBX59.01 Billion ≈ $7.18 Million |
-1.90% |
| 2022-12-31 | GBX60.15 Billion ≈ $7.32 Million |
-23.96% |
| 2021-12-31 | GBX79.10 Billion ≈ $9.62 Million |
-1.65% |
| 2020-12-31 | GBX80.43 Billion ≈ $9.79 Million |
+0.93% |
| 2019-12-31 | GBX79.69 Billion ≈ $9.70 Million |
+37.24% |
| 2018-12-31 | GBX58.07 Billion ≈ $7.06 Million |
+2.99% |
| 2017-12-31 | GBX56.38 Billion ≈ $6.86 Million |
-4.57% |
| 2016-12-31 | GBX59.08 Billion ≈ $7.19 Million |
+10.54% |
| 2015-12-31 | GBX53.45 Billion ≈ $6.50 Million |
+31.48% |
| 2014-12-31 | GBX40.65 Billion ≈ $4.95 Million |
-3.41% |
| 2013-12-31 | GBX42.09 Billion ≈ $5.12 Million |
+1.47% |
| 2012-12-31 | GBX41.48 Billion ≈ $5.05 Million |
+0.96% |
| 2011-12-31 | GBX41.08 Billion ≈ $5.00 Million |
-2.31% |
| 2010-12-31 | GBX42.05 Billion ≈ $5.12 Million |
-1.89% |
| 2009-12-31 | GBX42.86 Billion ≈ $5.22 Million |
+8.81% |
| 2008-12-31 | GBX39.39 Billion ≈ $4.79 Million |
+27.06% |
| 2007-12-31 | GBX31.00 Billion ≈ $3.77 Million |
+21.33% |
| 2006-12-31 | GBX25.55 Billion ≈ $3.11 Million |
-6.05% |
| 2005-12-31 | GBX27.20 Billion ≈ $3.31 Million |
+18.54% |
| 2004-12-31 | GBX22.94 Billion ≈ $2.79 Million |
+8.23% |
| 2003-12-31 | GBX21.20 Billion ≈ $2.58 Million |
-5.05% |
| 2002-12-31 | GBX22.33 Billion ≈ $2.72 Million |
+1.65% |
| 2001-12-31 | GBX21.97 Billion ≈ $2.67 Million |
+1.74% |
| 2000-12-31 | GBX21.59 Billion ≈ $2.63 Million |
+107.06% |
| 1999-12-31 | GBX10.43 Billion ≈ $1.27 Million |
+11.57% |
| 1998-12-31 | GBX9.35 Billion ≈ $1.14 Million |
+10.77% |
| 1997-12-31 | GBX8.44 Billion ≈ $1.03 Million |
+1.48% |
| 1996-12-31 | GBX8.31 Billion ≈ $1.01 Million |
-2.66% |
| 1995-12-31 | GBX8.54 Billion ≈ $1.04 Million |
+5.42% |
| 1995-06-30 | GBX8.10 Billion ≈ $985.79K |
+2.73% |
| 1994-06-30 | GBX7.89 Billion ≈ $959.62K |
+5.75% |
| 1993-06-30 | GBX7.46 Billion ≈ $907.42K |
+31.26% |
| 1992-06-30 | GBX5.68 Billion ≈ $691.34K |
-1.08% |
| 1991-06-30 | GBX5.74 Billion ≈ $698.88K |
+27.87% |
| 1990-06-30 | GBX4.49 Billion ≈ $546.55K |
+29.49% |
| 1989-06-30 | GBX3.47 Billion ≈ $422.08K |
+21.00% |
| 1988-06-30 | GBX2.87 Billion ≈ $348.83K |
+21.59% |
| 1987-06-30 | GBX2.36 Billion ≈ $286.90K |
+30.78% |
| 1986-06-30 | GBX1.80 Billion ≈ $219.37K |
-- |
About GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more